about
Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology GroupAnthracyclines: cardiotoxicity and its prevention.A supramolecular nanovehicle toward systematic, targeted cancer and tumor therapy.Early identification of anthracycline cardiomyopathy: possibilities and implications.A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists.A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.Preparation and tumor cell model based biobehavioral evaluation of the nanocarrier system using partially reduced graphene oxide functionalized by surfactant.Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer.A phase II trial of paclitaxel and epirubicin in advanced breast cancer.Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutationsAnthracycline cardiotoxicity in childhood.Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.Contradistinction between doxorubicin and epirubicin: in-vitro interaction with blood components.Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications.
P2860
Q33232092-0AEA8CB3-A499-4C02-A65A-AF3E0F9D73C0Q33336786-81AD9012-0B6A-488F-AD89-13A78C411B3CQ33488519-B85A3713-2E27-40B0-B2E4-3179F2251301Q33625243-CA9449A9-DF08-43D3-A401-433BDE51DDE2Q33893363-0D8AAA22-280B-474B-8216-C9AB6F399EC2Q34800157-B719F7E1-DB05-4FE9-8CAC-882DB27EE326Q34855129-D995D328-B620-45AF-B92D-7F7DFDA804B4Q35076343-EC4AF49A-1737-4359-BD20-51840BBA71D5Q35086595-B2F3916D-AE83-4883-9D0C-597D0061E087Q35729112-60C0DFF6-81B1-453C-B020-1E2DABA44F38Q36134870-05F3B1AF-BF68-4A56-99D0-C3D88D31DAB9Q36431680-CF979E79-FCAD-41D6-90C0-1574C30EBC3DQ36642165-E2DB54D9-1C98-426B-9A08-C08B65BBE139Q36749303-67FC3779-F0C7-46AE-827C-DE7AB414D86DQ37165394-0BFE098A-7061-48A6-BF82-D65BBDDB7CB9Q43503224-7FAE40EA-10C5-4100-BCBF-0053D852D97CQ43655074-50B76AD0-E17C-4223-8942-6209B854430EQ43692560-D08F01E7-0763-4DB0-AD0A-91C2FE63394FQ47589446-7ABE1F73-615D-4BEC-9457-C441862518EA
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Drugs ten years later: epirubicin.
@en
type
label
Drugs ten years later: epirubicin.
@en
prefLabel
Drugs ten years later: epirubicin.
@en
P2093
P1433
P1476
Drugs ten years later: epirubicin
@en
P2093
G Bonadonna
P Valagussa
R Demicheli
V Bonfante
P304
P356
10.1093/OXFORDJOURNALS.ANNONC.A058514
P50
P577
1993-05-01T00:00:00Z